Stragen Services S.A.S
Stragen Services S.A.S is recorded as a service provider in 6 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 6 of 6 trials · Latest update first
A two-part, open-label, clinical study to assess the safety, tolerability and activity of intravenous doses of ICT01 in combination with low-dose subcutaneous interleukin-2 in patients with advanced solid tumors (EVICTION-2)
Sponsor Imcheck Therapeutics
- Start (EU)
- Latest update
- Estimated end
Operational learnings available3 trial-level findings · Read insights
- The study enrolled 44 participants at five centers in France, Germany, and the United Kingdom.
- Protocol amendments modified inclusion criteria and added or clarified exclusion criteria.
- Protocol amendments increased the Part 1 sample size, added and omitted dose-escalation cohorts, and added pembrolizumab as study treatment.
These findings describe the trial, not the service provider’s performance or responsibility.
A Phase II/III, multicentre, 8-week run-in phase followed by a 12- week, prospective, parallel-group, double-blind, randomized withdrawal, placebo-controlled study, with a 52 week open label extension, to evaluate the efficacy and safety of daily 1.5 to 3.5 mg basimglurant in patients with pain associated with trigeminal neuralgia with suboptimal response to their current anti-pain therapy
Sponsor Noema Pharma AG
- Start (EU)
- Latest update
- Estimated end
A randomized, open-label, phase 3 trial comparing the efficacy and safety of OSE2101 versus docetaxel in HLA-A2 positive patients with metastatic Non-Small Cell Lung Cancer (NSCLC) and secondary resistance to Immune Checkpoint Inhibitor (ICI) - ARTEMIA study
Sponsor OSE Immunotherapeutics
- Start (EU)
- Latest update
- Estimated end
A multicenter phase 1/2 dose-finding and dose expansion study of OSE-279, a PD-1 blocking monoclonal antibody, in subjects with advanced solid tumors or lymphomas
Sponsor OSE Immunotherapeutics
- Start (EU)
- Latest update
- Estimated end
- Not reported
A global multicenter phase 1/2 trial of EO4010, a novel microbial-derived peptide therapeutic vaccine, in combination with nivolumab and/or bevacizumab, for treatment of patients with previously treated metastatic colorectal carcinoma (the "AUDREY" study).
Sponsor Enterome
- Start (EU)
- Latest update
- Estimated end
A Phase 2B, Multicenter, 30-week, Prospective, Cross-over, Double-blind, Randomized, Placebo-controlled Study Followed by a 52-Week Open-label Extension Study to Evaluate the Efficacy and Safety of Basimglurant Adjunctive to Ongoing Anticonvulsive Therapy in Children, Adolescents, and Young Adults with Seizures Associated with Tuberous Sclerosis Complex
Sponsor Noema Pharma AG
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Stragen Services S.A.S?
The 2026-10-09 snapshot links Stragen Services S.A.S to 6 distinct CTIS trials. Recorded services include Safety reporting & pharmacovigilance. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Stragen Services S.A.S?
The most frequently recorded therapeutic areas are Solid Tumor Oncology, Dermatology, Gastroenterology, Gynecology. Recorded phases include Phase 2, Phase 1, Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Stragen Services S.A.S conducted?
The linked trials record locations in 12 countries, including Spain, France, Germany, Italy, Poland. These are trial locations, not confirmed office locations or countries where Stragen Services S.A.S delivered services.
What can this page tell me about Stragen Services S.A.S's trial experience?
Browse 6 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 1 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Stragen Services S.A.S. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Stragen Services S.A.S.